[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628738":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":95,"collaborators":97,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":103,"sex":109,"minAge":110,"maxAge":26,"enrollmentInfo":111,"targetDuration":26,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Korea University Anam Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CART BP Pro-guided blood pressure management","EXPERIMENTAL","Participants will undergo ambulatory blood pressure monitoring using the CART BP Pro wearable device. Antihypertensive medication adjustments will be guided by ambulatory blood pressure data obtained from the device.",[13],"Device: CART BP Pro",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual care","ACTIVE_COMPARATOR","Participants will receive standard hypertension management based on office blood pressure measurements according to current clinical guidelines.",[19],"Other: Usual Care",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","CART BP Pro","CART BP Pro is a wearable cuffless continuous blood pressure monitoring device based on photoplethysmography technology that enables 24-hour ambulatory blood pressure measurement.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Usual Care","Antihypertensive medication adjustments are based on office blood pressure measurements obtained during routine outpatient visits.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Hyung Joon Joo, MD PhD","CONTACT","+821034760526","drjoohj@korea.ac.kr",[38,56,82],{"facility":39,"status":40,"city":41,"state":26,"zip":26,"country":42,"countryCode":26,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Korea University Ansan Hospital","RECRUITING","Ansan","South Korea",{"type":44,"coordinates":45},"Point",[46,47],126.52613,35.46836,{"lat":47,"lon":46},[50,54],{"name":51,"role":34,"phone":52,"phoneExt":26,"email":53},"Seung Yong Shin, MD PhD","+82-1088631078","theshin04@korea.ac.kr",{"name":51,"role":55,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"facility":5,"status":40,"city":57,"state":26,"zip":58,"country":42,"countryCode":26,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Seoul","02841",{"type":44,"coordinates":60},[61,62],126.9784,37.566,{"lat":62,"lon":61},[65,68,69,72,74,76,78,80],{"name":66,"role":34,"phone":67,"phoneExt":26,"email":36},"Hyung Joon Joo","+82-1034760526",{"name":33,"role":55,"phone":26,"phoneExt":26,"email":26},{"name":70,"role":71,"phone":26,"phoneExt":26,"email":26},"Cheol Woong Yu, MD PhD","SUB_INVESTIGATOR",{"name":73,"role":71,"phone":26,"phoneExt":26,"email":26},"Dong-Hyuk Cho, MD PhD",{"name":75,"role":71,"phone":26,"phoneExt":26,"email":26},"Jung-Joon Cha, MD PhD",{"name":77,"role":71,"phone":26,"phoneExt":26,"email":26},"Mi-Na Kim, MD PhD",{"name":79,"role":71,"phone":26,"phoneExt":26,"email":26},"Jae Hyoung Park, MD PhD",{"name":81,"role":71,"phone":26,"phoneExt":26,"email":26},"Se Won Oh, MD PhD",{"facility":83,"status":40,"city":57,"state":26,"zip":26,"country":42,"countryCode":26,"cosmosGeoPoint":84,"geoPoint":86,"contacts":87},"Korea University Guro Hospital",{"type":44,"coordinates":85},[61,62],{"lat":62,"lon":61},[88,92,93],{"name":89,"role":34,"phone":90,"phoneExt":26,"email":91},"Soohyung Park, MD PhD","+82-1031053710","shp503@naver.com",{"name":89,"role":55,"phone":26,"phoneExt":26,"email":26},{"name":94,"role":71,"phone":26,"phoneExt":26,"email":26},"Ji Eun Lee, MD",{"type":55,"investigatorFullName":66,"investigatorTitle":96,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Professor",[98],{"name":99,"class":100},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY","100628738","cart-bp-pro-guided-blood-pressure-management-for-uncontrolled-hypertension-100628738",false,"NCT07465549","CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension","Efficacy and Safety of Cuffless Ambulatory Blood Pressure Monitoring Device-Guided Blood Pressure Management Compared With Usual Care in Korean Patients With Uncontrolled Hypertension: A Multicenter Prospective Randomized Controlled Trial","CART-BP RCT","Inclusion Criteria:\n\n1. Age ≥ 19 years\n2. Uncontrolled hypertension defined as office systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg\n3. Ability and willingness to provide written informed consent and comply with study procedures\n\nExclusion Criteria:\n\n1. History of intolerance or contraindication to olmesartan, amlodipine, or hydrochlorothiazide\n2. Suspected secondary hypertension\n3. Atrial fibrillation\n4. Pregnancy or lactation\n5. Any serious medical condition that may interfere with study participation or interpretation of study results","ALL","19 Years",{"count":112,"type":113},400,"ESTIMATED","INTERVENTIONAL",[116],"NA","This multicenter, prospective, open-label randomized controlled trial evaluates the efficacy and safety of CART BP Pro-guided blood pressure management in Korean patients with uncontrolled hypertension. CART BP Pro is a wearable cuffless blood pressure monitoring device based on photoplethysmography technology that enables continuous ambulatory blood pressure monitoring.\n\nEligible participants with uncontrolled hypertension despite ongoing antihypertensive therapy will be randomly assigned in a 1:1 ratio to either a CART BP Pro-guided management group or a usual care group based on conventional office blood pressure measurements. Antihypertensive treatment in both groups will follow guideline-based therapy using standard agents including angiotensin receptor blockers, calcium channel blockers, and thiazide diuretics.\n\nThe primary efficacy endpoint is the between-group difference in 24-hour mean systolic blood pressure at 24 weeks measured using ambulatory blood pressure monitoring. Safety will be assessed by the incidence of treatment-emergent adverse events during the study period.",[119],"Hypertension",[119,121,122,123,23],"Ambulatory blood pressure monitoring","Cuffless blood pressure monitoring","Wearable blood pressure device","2026-04-26",{"date":126,"type":127},"2026-04-30","ACTUAL",{"date":129,"type":127},"2025-10-22",{"date":131,"type":113},"2027-07-31",{"name":5,"class":6},3]